We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Medicinal Products

202. Deputy Michael Fitzmaurice asked the Minister for Health her views on whether the current delay in the Skyclarys reimbursement negotiations aligns with the “equitable access” promised in the newly launched National Rare Disease Strategy 2025–2030; and if she will make a statement on the matter. [30663/26]

Comment on this